Companies: 48,687 Total Market Cap: 126956050782004.97

CSL Limited

ASX-CSL
Healthcare Biotechnology
Rank #239
Market Cap 79.96 B
Volume 565,400.55
Price 165.14
Change (%) 2.11%
Country or region Australia Australia

CSL Limited's latest marketcap:

79.96 B

As of May 2, 2025, CSL Limited's market capitalization has reached $79.96 B. According to our data, CSL Limited is the 239th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 79.96 B
Revenue (ttm) 15.85 B
Net Income (ttm) 2.86 B
Shares Out 484.21 M
EPS (ttm) 5.89
Forward PE 23.67
Ex-Dividend Date March 10, 2025
Earnings Date August 19, 2025
Market Cap Chart
Data Updated: May 2, 2025

CSL Limited's yearly market capitalization.

CSL Limited has seen its market value drop from A$128.84 B to A$115.90 B since 2020, representing a total decrease of 10.05% and an annual compound decline rate (CAGR) of 2.44%.
Date Market Cap Change (%)
April 17, 2025 A$115.90 B -15%
December 31, 2024 A$136.34 B -1.54%
December 29, 2023 A$138.48 B -0.2%
December 30, 2022 A$138.76 B -0.3%
December 31, 2021 A$139.18 B 8.03%
December 31, 2020 A$128.84 B

Company Profile

About CSL Limited

CSL Limited is a global biopharmaceutical company specializing in research, development, manufacturing, and distribution of innovative biotherapies and vaccines. Headquartered in Melbourne, Australia, CSL operates across multiple regions, including the United States, Germany, the United Kingdom, Switzerland, and China.

Business Segments

  • CSL Behring: Focuses on plasma-derived therapies, gene therapies, and recombinant products for rare and serious diseases.
  • CSL Seqirus: A leader in influenza vaccines, providing seasonal and pandemic flu solutions to governments and healthcare providers.
  • CSL Vifor: Specializes in treatments for iron deficiency and nephrology, addressing unmet medical needs in these therapeutic areas.

Company Overview

Founded in 1916, CSL Limited has grown into a trusted name in biopharmaceuticals, leveraging its intellectual property to advance medical science. The company remains committed to improving patient outcomes worldwide.

Frequently Asked Questions

As of May 2, 2025, CSL Limited (including the parent company, if applicable) has an estimated market capitalization of $79.96 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

CSL Limited global market capitalization ranking is approximately 239 as of May 2, 2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region Australia
Founded 1916
IPO Date n/a
Employees 32,698
CEO Paul McKenzie
Sector Healthcare
Industry Biotechnology
Address 655 Elizabeth Street
Melbourne, VIC 3000
Australia